Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 31 min ago
Peer-reviewedCC BY-NC-ND 4.0ESMO Open

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

  • R. Kanesvaran1
  • V. Gruenwald2
  • A. Wong3
  • J. Chan1
  • X. Yaoi4
  • N.A. Mulansari5
  • T.P. Sahoo6
  • Y. Miura7
  • H. Kim8
  • M. Saad9
  • M. Talag-Espinosa10
  • Y.-L. Su11
16 more authors
  • P. Chansriwong12
  • C. Charoentum13
  • Y.-C. Tsai14
  • C. Lola15
  • M. Thiagarajan16
  • S.H. Park17
  • C. Kondoh18
  • I. Shaikh19
  • A.R.A.H. Hamid20
  • F. Zhou21
  • D. Trapani22
  • E. Lim1
  • D. Ang1
  • T.W. Chong1
  • E. Poon1
  • M. Schmidinger23
23 affiliations
  1. 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore
  2. 2Carolus Institute for Urologic Oncology, University Hospital Essen, Germany
  3. 3Department of Haemato-Oncology, National University Cancer Institute Singapore, Singapore
  4. 4Oncology Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
  5. 5Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
  6. 6Silverline Hospital, Bhopal, Madhya Pradesh, India
  7. 7Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Koto-ku, Tokyo, Japan
  8. 8Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea
  9. 9Department of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
  10. 10Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, The Philippines
  11. 11Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
  12. 12Division of Medical Oncology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  13. 13Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  14. 14Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
  15. 15Section of Medical Oncology, National Kidney and Transplant Institute, Quezon City, The Philippines
  16. 16Department of Radiotherapy and Oncology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
  17. 17Division of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  18. 18Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  19. 19Department of Medical Oncology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India
  20. 20Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  21. 21Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China
  22. 22Department of Medical Oncology, Università degli Studi di Milano, Milan, Italy
  23. 23Department of Urology, Medical University of Vienna, Vienna, Austria
Read full textPDFDOICite

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma (RCC) were published in May 2024 and adapted in December 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with RCC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with RCC representing the oncological societies of China [Chinese Society of Clinical Oncology (CSCO)], Indonesia [Indonesian Society of Hematology and Medical Oncology (ISHMO)], India [Indian Society of Medical and Paediatric Oncology (ISMPO)], Japan [Japanese Society of Medical Oncology (JSMO)], Korea [Korean Society of Medical Oncology (KSMO)], Malaysia [Malaysian Oncological Society (MOS)], The Philippines [Philippine Society of Medical Oncology (PSMO)], Singapore [Singapore Society of Oncology (SSO)], Taiwan [Taiwan Oncology Society (TOS)] and Thailand [Thai Society of Clinical Oncology (TSMO)], coordinated by ESMO and the SSO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with RCC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in drug approvals and reimbursement strategies between the different regions.

Related

  1. Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.
    Marco Ladetto, Natacha Bolaños, Guy Bouguet +15
    HemaSpherePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer
    Daniel Arnoldus Korevaar, Bojan Kovacevic, Efthymia Papadopoulou +22
    European Respiratory JournalPeer-reviewedLicence not stated10 citedGeneral medicineOpenAlex
  3. Artificial intelligence-assisted bronchoscopy for the diagnosis and treatment of pulmonary diseases: Advances and clinical practice
    Guoliang Zhang, Yidan Qing, Xianwen Sun +5
    Journal of translational internal medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCEurope PMCPMC
  4. Clinical guidelines for the diagnosis and management of pediatric fecal incontinence: A comprehensive review and treatment algorithm
    Mohammed Al-Beltagi
    World Journal of Clinical PediatricsPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  5. Primary pulmonary NUT carcinoma: pathological features, clinical diagnosis, treatment, and prognosis — An extended review
    Shan Wu, Miao Zhang, Hui Wang
    Oncology reviewsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kanesvaran2026panasian,
  title = {{Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma}},
  author = {R. Kanesvaran and V. Gruenwald and A. Wong and J. Chan and X. Yaoi and N.A. Mulansari and T.P. Sahoo and Y. Miura and H. Kim and M. Saad and M. Talag-Espinosa and Y.-L. Su and P. Chansriwong and C. Charoentum and Y.-C. Tsai and C. Lola and M. Thiagarajan and S.H. Park and C. Kondoh and I. Shaikh and A.R.A.H. Hamid and F. Zhou and D. Trapani and E. Lim and D. Ang and T.W. Chong and E. Poon and M. Schmidinger},
  journal = {ESMO Open},
  year = {2026},
  month = oct,
  doi = {10.1016/j.esmoop.2026.108552},
  url = {https://doi.org/10.1016/j.esmoop.2026.108552},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
AU  - R. Kanesvaran
AU  - V. Gruenwald
AU  - A. Wong
AU  - J. Chan
AU  - X. Yaoi
AU  - N.A. Mulansari
AU  - T.P. Sahoo
AU  - Y. Miura
AU  - H. Kim
AU  - M. Saad
AU  - M. Talag-Espinosa
AU  - Y.-L. Su
AU  - P. Chansriwong
AU  - C. Charoentum
AU  - Y.-C. Tsai
AU  - C. Lola
AU  - M. Thiagarajan
AU  - S.H. Park
AU  - C. Kondoh
AU  - I. Shaikh
AU  - A.R.A.H. Hamid
AU  - F. Zhou
AU  - D. Trapani
AU  - E. Lim
AU  - D. Ang
AU  - T.W. Chong
AU  - E. Poon
AU  - M. Schmidinger
PY  - 2026
DA  - 2026/10/01
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2026.108552
UR  - https://doi.org/10.1016/j.esmoop.2026.108552
AB  - The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma (RCC) were published in May 2024 and adapted in December 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with RCC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with RCC representing the oncological societies of China [Chinese Society of Clinical Oncology (CSCO)], Indonesia [Indonesian Society of Hematology and Medical Oncology (ISHMO)], India [Indian Society of Medical and Paediatric Oncology (ISMPO)], Japan [Japanese Society of Medical Oncology (JSMO)], Korea [Korean Society of Medical Oncology (KSMO)], Malaysia [Malaysian Oncological Society (MOS)], The Philippines [Philippine Society of Medical Oncology (PSMO)], Singapore [Singapore Society of Oncology (SSO)], Taiwan [Taiwan Oncology Society (TOS)] and Thailand [Thai Society of Clinical Oncology (TSMO)], coordinated by ESMO and the SSO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with RCC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in drug approvals and reimbursement strategies between the different regions.
SN  - 2059-7029
ER  -